PlumX Metrics
Embed PlumX Metrics

Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: A phase II study

British Journal of Cancer, ISSN: 0007-0920, Vol: 95, Issue: 3, Page: 260-265
2006
  • 33
    Citations
  • 0
    Usage
  • 44
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

The safety and efficacy of gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with resected pancreatic cancer was determined. Patients with resected adenocarcinoma of the pancreas were treated with intravenous gemcitabine administered twice-weekly (40 mg m) for 5 weeks concurrent with upper abdominal radiation (50.4 Gy in 5 weeks). At the completion of the chemoradiation, patients without disease progression were given gemcitabine (1000 mg m) weekly for two cycles. Each cycle consisted of 3 weeks of treatment followed by 1 week without treatment. Forty-seven patients were entered, 46 of whom are included in this analysis. Characteristics: median age 61 years (range 35-79); 24 females (58%); 73% stage T3/T4; and 70% lymph node positive. Grade III/IV gastrointestinal or haematologic toxicities were infrequent. The median survival was 18.3 months, while the median time to disease recurrence was 10.3 months. Twenty-four percent of patients were alive at 3 years. Only six of 34 patients with progression experienced local regional relapse as a component of the first site of failure. These results confirm the feasibility of delivering adjuvant concurrent gemcitabine and radiation to the upper abdomen. This strategy produced good local regional tumour control. © 2006 Cancer Research.

Bibliographic Details

A. W. Blackstock; L. D. Case; S. A. Melin; E. A. Levine; G. Mishra; F. Mornex; C. Partensky; L. Descos; S. A. Limentani; L. A. Kachnic; J. E. Tepper

Springer Science and Business Media LLC

Medicine; Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know